Axtria Presents Two HEOR/RWE Studies At ISPOR Europe 2022

(MENAFN- GlobeNewsWire - Nasdaq)

Vienna, Austria, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Axtria, a global cloud software, integrated RWE/HEOR analytics solutions provider, and AI/ML technology leader for the life sciences industry, will present two posters at this year's conference that combine different modeling methods with the latest advanced analytics technologies. Both will highlight the clinical and economic benefits of anti-arrhythmic drugs (AADs) for treating atrial fibrillation (AFib) as well as glargine insulin for treating type 2 diabetes.

The poster findings underscore Axtria's work leading the evolution of advanced data analytics and intelligent software technology in the application of different real world evidence (RWE) research into advanced value-based models. Axtria's latest thought leadership in this area, a white paper titled “Seeing the Whole Elephant: Integrated Data Analytics in Support of RWE” addresses the emergence of integrated RWE/HEOR analytics. This white paper can be found in .

The first Axtria poster, Clinical and Economic Outcomes Associated with Use of Anti-Arrhythmic Drugs Versus Ablation in Atrial Fibrillation (AFib) , to be presented on Monday, November 7 at 15:00 (CET), utilizes a modeling approach called Rhythm Control to demonstrate the cost benefits of AADs compared to ablation as a treatment for AFib. The second Axtria poster, The Economic Value of Insulin Glargine 300 U/Ml (GLA-300) in People ≥18 Years of Age with Type 2 Diabetes Mellitus: A Value-Based Economic Model from a U.S. Payer Perspective , to be presented on Tuesday, November 8 at 15:00 (CET), uses another approach called prevalence-based value-based modeling to demonstrate the value and affordability of the insulin biosimilar glargine (Gla-300) over basal insulins for treating type 2 diabetes.

Axtria's two posters at ISPOR Europe 2022 follow research the company presented at ISPOR 2022 last May that showed the cost-lowering and therapeutic benefits of administering dronedarone versus other AAD drug combinations in treating AFib ( ).

“With the evolution in new and advanced analytics and AI/ML models, overlaying and combining these models with the diversity of traditional RWE study approaches and an ever-growing range of clinical and patient data sets, the field of HEOR has never been in a better position to help all healthcare decisionmakers determine the most effective and cost-efficient drug therapies and treatment regimens for patients across multiple disease categories,“ said Won Chan Lee, Principal and Head, RWE/HEOR, Axtria.“We look forward to sharing the results of our work in integrated RWD/RWE analytics with the HEOR professional community at ISPOR Europe 2022 via our poster findings. We feel that our posters shed significant new light on what therapies show the best value and benefits in such diverse diseases and conditions as type 2 diabetes and AFib,” added Lee.

To schedule a meeting with Axtria's HEOR team at ISPOR Europe 2022 and/or to learn more about Axtria's integrated RWE/HEOR analytics solutions, please click .

About Axtria
Axtria is a global provider of cloud software and data analytics to the life sciences industry, helping companies transform the product commercialization journey to drive sales growth and improve patient healthcare outcomes. Axtria strongly focuses on sales and marketing operations. With customers in over 75 countries, Axtria is one of the life sciences industry's most prominent global commercial solutions providers.

Axtria helps customers improve operational effectiveness with solutions that leverage Big Data, cloud software, predictive analytics, artificial intelligence, and machine learning. Axtria DataMAx™, Axtria InsightsMAx™, Axtria SalesIQ™, Axtria MarketingIQ™, and Axtria CustomerIQ™ are cloud-based software platforms that enable customers to efficiently manage data, deliver insights for sales and marketing planning, and manage end-to-end commercial operations. For more information, visit  . 

Connect with Axtria on:

  • LinkedIn: 
  • Facebook:
  • Twitter:
  • Instagram: 

Axtria, Axtria SalesIQ™, Axtria CustomerIQ™, Axtria Marketing IQ™, Axtria InsightsMAx™, and Axtria DataMAx™ are trademarks or registered trademarks of Axtria. Other names may be trademarks of their respective owners.



Axtria at ISPOR Europe 2022 Axtria Presents Two HEOR/RWE Studies at ISPOR Europe 2022 Tags Related Links


GlobeNewsWire - Nasdaq

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.